YODAs Ordinære Generalforsamling 2018

Yngre Ortopædkirurger Danmark (YODA) inviterer alle medlemmer til ordinær generalforsamling
Onsdag 24. oktober 2018 kl. 17.30

Generalforsamlingen afholdes på Hotel Radisson. Se programmet for DOS Kongressen for præcis location.
Generalforsamlingen er åben for alle medlemmer og afholdes fra kl. 17.30-19.00. Er du ikke medlem af YODA kan indmeldelse ske på dagen.

Der vil være snacks og drikkevarer under generalforsamlingen. Bagefter går vi i samlet flok til Café Langebro (200 m fra Radisson) hvor der vil være et let aftensmåltid og drikkevarer til rimelige priser. Deltagelse i aftenarrangementet på Langebro kræver tilmelding.

Seneste frist for tilmelding/afmelding er 17. oktober 2018
Tilmelding åbner medio september på www.yngreortopaedkirurger.dk

Vel mødt!

Hvem skal modtage Den Gyldne Yoda 2018?

Den Gyldne Yoda gives hvert år til en person eller afdeling, som gør en særlig indsats for uddannelse af yngre ortopædkirurger. Hvem der skal modtage årets eftertragtede pris, er du med til at bestemme.

Hvis det er din afdeling, vejleder, underviser, leder eller anden kollega, som går en ekstra mil for at uddanne og inspirere, så indstil vedkommende som modtager af Den Gyldne Yoda 2018.

Sådan gør du: Skriv en begrundet indstilling hvor du/I fortæller hvorfor netop jeres kandidat bør modtage prisen og send den til uddannelse@yngreortopaedkirurger.dk inden d. 13. oktober 2018.

Prisen uddeles til gallamiddagen på årets DOS-kongres.

Vi glæder os til at høre fra jer!

YODAs Uddannelsesudvalg

Forskning

Denne måneds “One to Watch” omhandler den berømte Tennisalbue som alle ortopædkirurger vel har stiftet bekendtskab med. Som kirurg er det en utaknemmelig diagnose. Det kan være ganske invaliderende for patienterne mens det står på, men for langt de fleste går det over med tiden. For de kroniske tilfælde findes en række behandlingsmuligheder, hvoraf ingen har overvældende effekt. Der kan skinnebehandles, anlægges blokade eller endda kan overskæring af ekstensorfæstet komme på tale. Dette studie er et dobbelt-blindet RCT der påviser en betydende analgetisk effekt af Botox injektion. Det er et studie med kort follow-up (kun 3 mdr), men under alle omstændigheder spændende, synes jeg. God fornøjelse.

One to Watch

Creuz´e A,  Petit A, S`eze M. Short-Term Effect of Low-Dose, Electromyography-Guided Botulinum Toxin A Injection in the Treatment of Chronic Lateral Epicondylar Tendinopathy – A Randomized, Double-Blinded Study. J Bone Joint Surg Am. 2018;100:818-26

Background: Botulinum toxin A (BoNT-A) is a novel treatment for chronic lateral epicondylar tendinopathy. Preliminary studies have demonstrated promising results; however, confirmation of the effectiveness of BoNT-A treatment and further assessment of its side effects are required. This study investigated the analgesic effects of BoNT-A in the treatment of chronic lateral epicondylar tendinopathy.

Methods: This was a phase-III, single-center, randomized, double-blinded, placebo-controlled study including 60 patients with chronic lateral epicondylar tendinopathy that had been resistant to treatment for >6 months. Patients received either a 40-IU injection of BoNT-A or saline solution placebo into the extensor carpi radialis brevis (ECRB) muscle, aided by electromyographic (EMG) stimulation. Follow-up was 3 months. The primary assessment criterion was the percentage of patients whose pain was reduced by >50% at 90 days after injection. Secondary outcomes, including pain intensity, pain frequency, interference with quality of life, sick leave taken, maximum grip strength, and side effects, were assessed at days 30 and 90, and the number of participants per group requesting additional therapies at day 90 was recorded.

Results: Twenty-nine patients in the BoNT-A group and 28 patients in the placebo group were included in the day-90 analysis. Fifteen (51.7%) of the patients who were administered BoNT-A and 7 (25%) of the patients who received placebo reported a >50% reduction in initial pain intensity at day 90 (p = 0.005). Pain intensity and the effect on quality of life, measured using visual analog

scales, were both significantly lower in the group treated with BoNT-A compared with placebo at day 90 (p < 0.05). The rate of clinically detected transitory paresis of the third finger on extension was 17.2% in the BoNT-A group, with no associated functional impairment.

Conclusions: BoNT-A at 40 IU injected into the ECRB is an effective treatment for chronic lateral epicondylar tendinopathy that has been otherwise resistant to medical treatment. The rate of paresis of the third finger was low, with no associated functional impairment.

Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

Søren Ohrt-Nissen, Forskningsansvarlig

Syd